In this paper we discuss pathogenetic mechanisms of cardiovascular risk reduction in patients with type 2 diabetes mellitus by glucagon-like peptide 1 (GLP-1) receptor agonists. Results of experimental studies and randomized clinical studies are presented, and perspectives for using GLP-1 agonists in patients with diabetic cardiovascular complications are described.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.18565/cardio.2014.7.92-96 | DOI Listing |
Publication Analysis
Top Keywords
glucagon-like peptide
8
[cardioprotective effects
4
effects glucagon-like
4
peptide receptor
4
receptor agonists]
4
agonists] paper
4
paper discuss
4
discuss pathogenetic
4
pathogenetic mechanisms
4
mechanisms cardiovascular
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!